DaVita Inc. $DVA Shares Sold by GAMMA Investing LLC

GAMMA Investing LLC lowered its stake in DaVita Inc. (NYSE:DVA) by 5.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,447 shares of the company’s stock after selling 88 shares during the quarter. GAMMA Investing LLC’s holdings in DaVita were worth $206,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Doma Perpetual Capital Management LLC increased its holdings in DaVita by 172.3% in the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock valued at $44,110,000 after purchasing an additional 182,476 shares during the last quarter. Northern Trust Corp raised its holdings in shares of DaVita by 20.2% in the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after buying an additional 149,858 shares during the period. Nuveen LLC acquired a new position in DaVita during the 1st quarter worth about $20,218,000. Rovin Capital UT ADV purchased a new position in DaVita during the 1st quarter valued at about $18,442,000. Finally, Amundi grew its position in DaVita by 16.0% in the 1st quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after acquiring an additional 71,304 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DVA. Bank of America reduced their price target on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research report on Wednesday, September 10th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Barclays dropped their price target on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. Finally, Truist Financial set a $148.00 price objective on DaVita in a research note on Friday, August 8th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $158.00.

Insider Buying and Selling at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

DaVita Trading Up 0.6%

NYSE DVA opened at $131.08 on Monday. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60. The firm has a 50 day moving average of $136.16 and a two-hundred day moving average of $140.53. The stock has a market capitalization of $9.37 billion, a PE ratio of 12.89, a price-to-earnings-growth ratio of 0.94 and a beta of 1.13. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the previous year, the firm posted $2.00 earnings per share. The company’s revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.